https://www.pharmaradar360.com/article/f3cf5fe2308c83ecPharmaRadar360en2026-04-14T13:41:02.000ZInterfarma no HBR Summit Brasil: cuidado baseado em valor é caminho para mais eficiência e melhores desfechos em saúdehttps://www.pharmaradar360.com/article/febb72a16f92c72aPharmaRadar360en2026-04-14T13:38:04.000ZUpdate on Construction of New Plasma-Derived Therapies Manufacturing Facility in Juso, Osaka | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/49596db5be21d02fPharmaRadar360en2026-04-14T13:38:04.000Z20,000+ Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 countries | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/4c473af8e0fbba70PharmaRadar360en2026-04-14T13:38:04.000ZTakeda Announces Completion of Acquisition of Own Shares | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/b3df3da3141e2541PharmaRadar360en2026-04-14T13:38:04.000ZGAMMAGARD LIQUID ERC Approved for Primary Immunodeficiencyhttps://www.pharmaradar360.com/article/0822375a17c0bd15PharmaRadar360en2026-04-14T13:38:04.000ZFiling of Corporate Governance Report to the Tokyo Stock Exchange | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/9d01a338763f48f6PharmaRadar360en2026-04-14T13:38:04.000ZTakeda Announces the Pricing Terms of the Previously Announced Cash Tender Offers for Certain Outstanding Notes | Takedahttps://www.pharmaradar360.com/article/93cdc620ada882fbPharmaRadar360en2026-04-14T13:38:04.000ZTakeda Announces New Assignments of Directorshttps://www.pharmaradar360.com/article/fc204f1fc516c285PharmaRadar360en2026-04-14T13:37:57.000ZStatement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congresshttps://www.pharmaradar360.com/article/19683ea67614dfecPharmaRadar360en2026-04-14T13:37:57.000ZTakeda Reports Third-Quarter FY2025 Results | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/be921822b3782fa3PharmaRadar360en2026-04-14T13:37:57.000ZTakeda Phase 3 Study Results in Pediatric Ulcerative Colitishttps://www.pharmaradar360.com/article/bcdf75694a45a3b2PharmaRadar360en2026-04-14T13:37:57.000ZRusfertides Phase 3 Trial for Polycythemia Vera at ASCO 2025https://www.pharmaradar360.com/article/e4636f949c687c8bPharmaRadar360en2026-04-14T13:37:57.000ZTakeda Presents Long-Term Data from ADVANCE-CIDP 3 Trial of HYQVIAhttps://www.pharmaradar360.com/article/f48c3647ab28f713PharmaRadar360en2026-04-14T13:37:57.000ZTakeda to Hold Third Quarter FY2022 Earnings Call on February 2https://www.pharmaradar360.com/article/9f590c223b59a084PharmaRadar360en2026-04-14T13:37:57.000ZTakeda Receives Approval to Manufacture and Market Entyvio® Subcutaneous Injection in Japan for the Maintenance Treatment of Moderate to Severe Ulcerative Colitishttps://www.pharmaradar360.com/article/f70640ce922ee02ePharmaRadar360en2026-04-14T13:37:44.000ZNotice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japanhttps://www.pharmaradar360.com/article/e6fc351dbf599bfbPharmaRadar360en2026-04-14T13:37:44.000ZADZYNMA® Receives European Commission Approval as First Recombinant ADAMTS13 Therapy for cTTPhttps://www.pharmaradar360.com/article/135d7003c473d4e8PharmaRadar360en2026-04-14T13:37:44.000ZU.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Olderhttps://www.pharmaradar360.com/article/7cdad0f9bfe50a36PharmaRadar360en2026-04-14T13:37:44.000ZTakeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitorhttps://www.pharmaradar360.com/article/010103043cccafaaPharmaRadar360en2026-04-14T13:37:44.000ZTakeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiaryhttps://www.pharmaradar360.com/article/15ea49aded7a9ddaPharmaRadar360en2026-04-14T13:37:44.000ZFDA Accepts Takeda’s Entyvio BLAhttps://www.pharmaradar360.com/article/b68e3e4bab369ce0PharmaRadar360en2026-04-14T12:50:00.000ZErin Lichy Gets Real About Her Natrelle® Breast Augmentationhttps://www.pharmaradar360.com/article/45a66b8315871e3dPharmaRadar360en2026-04-14T12:00:00.000ZCommunity Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinicshttps://www.pharmaradar360.com/article/9ac778cddbd84a41PharmaRadar360en2026-04-14T12:00:00.000ZAmneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.https://www.pharmaradar360.com/article/0e8229e036e90c55PharmaRadar360en2026-04-14T11:00:00.000ZTiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congresshttps://www.pharmaradar360.com/article/67d722a77e2f284dPharmaRadar360en2026-04-14T10:47:33.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/15882150685c46cePharmaRadar360en2026-04-14T10:45:23.000ZAvacta CEO Christina Coughlin Named as One of In Vivo’s 2026 Rising Leadershttps://www.pharmaradar360.com/article/cb37dc9f36352675PharmaRadar360en2026-04-14T10:07:42.000ZMedicines: Get integrated scientific advice from the MHRA and NICEhttps://www.pharmaradar360.com/article/aba390c444060812PharmaRadar360en2026-04-14T03:00:00.000Z[ANZEN]MHLW Pharmaceuticals and Medical Devices Safety Information No.428 postedhttps://www.pharmaradar360.com/article/c3a81933f934f01aPharmaRadar360en2026-04-14T03:00:00.000Z[SHINSA]The information of New Drug Review with Electronic Data updatedhttps://www.pharmaradar360.com/article/9728db84153b2920PharmaRadar360en2026-04-14T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/5af3c3e18e13dc2ePharmaRadar360en2026-04-14T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/b5a6360a869b8781PharmaRadar360en2026-04-14T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/e3cf6f4a9f6b9839PharmaRadar360en2026-04-14T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/5d25a98f310c4c5ePharmaRadar360en2026-04-14T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/2ac2b648dc9f5f83PharmaRadar360en2026-04-14T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/1e0096b2d0f28415PharmaRadar360en2026-04-14T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/dc8244a557ae7cc2PharmaRadar360en2026-04-14T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/c70558c83f5ffda9PharmaRadar360en2026-04-14T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/991c21c2701f5051PharmaRadar360en2026-04-14T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/03b10716a1c9858dPharmaRadar360en2026-04-14T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/19bf41f6bbdeeff5PharmaRadar360en2026-04-14T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/c865eb39e007379bPharmaRadar360en2026-04-14T00:00:00.000Z6203https://www.pharmaradar360.com/article/e524501f2a681a99PharmaRadar360en2026-04-14T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/853ebb17588ca640PharmaRadar360en2026-04-14T00:00:00.000ZBausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Orderinghttps://www.pharmaradar360.com/article/150216043325e375PharmaRadar360en2026-04-13T17:47:48.000ZBiotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzenhttps://www.pharmaradar360.com/article/892e2f0811883ca0PharmaRadar360en2026-04-13T13:56:15.000ZField Safety Notices: 6 to 10 April 2026https://www.pharmaradar360.com/article/9046ef89ff0eb153PharmaRadar360en2026-04-13T13:08:52.000ZRepenser la santé depuis les territoires : le signal venu de Dunkerquehttps://www.pharmaradar360.com/article/540cdf7393f51d9bPharmaRadar360en2026-04-13T12:24:45.000ZDecision: Triheptanoin in the treatment of long-chain fatty acid oxidation disorders (LC-FAOD)https://www.pharmaradar360.com/article/17606c0a5a9b4d51PharmaRadar360en2026-04-13T11:48:37.000ZNervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conferencehttps://www.pharmaradar360.com/article/611677eb72f3fcbePharmaRadar360en2026-04-13T11:17:53.000ZEl Informe Anual sobre Cosmetovigilancia registra un aumento del 30% de las notificaciones por efectos no deseados de productos cosméticoshttps://www.pharmaradar360.com/article/1f0b078c77f0622fPharmaRadar360en2026-04-13T11:17:42.000ZDecision: Marketing authorisations granted in 2025https://www.pharmaradar360.com/article/3a1b056abb9791d3PharmaRadar360en2026-04-13T11:00:00.000ZIfinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapyhttps://www.pharmaradar360.com/article/add5af149e28f404PharmaRadar360en2026-04-13T10:45:00.000ZLilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLLhttps://www.pharmaradar360.com/article/b45893a1deb7e1c9PharmaRadar360en2026-04-13T10:00:00.000ZMedtronic to announce financial results for its fourth quarter and full fiscal year 2026https://www.pharmaradar360.com/article/ad6504852721b264PharmaRadar360en2026-04-13T05:00:00.000ZRoche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosishttps://www.pharmaradar360.com/article/0f710c111f870505PharmaRadar360en2026-04-13T05:00:00.000ZThe role of biomarkers: how new modalities are making precision medicine a realityhttps://www.pharmaradar360.com/article/02af197f88ab392bPharmaRadar360en2026-04-13T03:00:00.000Z[IBENTO][IBENTO]The report for the PMDA-ATC Pharmacovigilance Seminar 2026 has been posted.https://www.pharmaradar360.com/article/1f15d45363267479PharmaRadar360en2026-04-13T03:00:00.000Z[SONOTA]Recent Publications by PMDA Staff updatedhttps://www.pharmaradar360.com/article/14b95a4514bb1516PharmaRadar360en2026-04-13T03:00:00.000Z[KOKUSAI]The report for the APEC CoE workshop: PMDA-ATC Pharacovigilance Seminar 2026 has been posted.https://www.pharmaradar360.com/article/4d6870b38d5595e3PharmaRadar360en2026-04-13T03:00:00.000Z[KOKUSAI]PMDA-ATC E-Learning Course contents have been released for FY2026https://www.pharmaradar360.com/article/54cabc71d5344dd7PharmaRadar360en2026-04-13T00:00:00.000Z2026å¹´4月13日 ニュースリリース ã‚¢ãƒ«ãƒ„ãƒã‚¤ãƒžãƒ¼ç— é–¢é€£ã€è¡€æ¶²ä¸­ã®p-Tau217ã‚’æ¸¬å®šã™ã‚‹ç ”ç©¶ç”¨è©¦è–¬ã‚’ç™ºå£²https://www.pharmaradar360.com/article/b88ffa2d02a08aabPharmaRadar360en2026-04-13T00:00:00.000ZSysmex Launches an Assay Kit for Identifying p-Tau217 in the Blood, a Biomarker Related to Alzheimer's Diseasehttps://www.pharmaradar360.com/article/82c82f3e675d6931PharmaRadar360en2026-04-13T00:00:00.000ZSysmex to Serve as Special Sponsor of Kobe Marathon 2026 – Supporting the Event Toward a Healthy, Prosperous Society and Vibrant Local Communities –